sports
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
SHANGHAI and HONG KONG, Sept. 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies,...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Fantasy Football Rankings: Hayden Winks' RB Blueprint for Week 4
Yahoo Sports
Indiana Created a Blueprint for an Impossible Turnaround. Now, Northwestern Is Building Even Bigger.
Sports Illustrated
49ers practice report: Mykel Williams returns from ACL injury
NBC Sports Bay Area & California
John Harbaugh on releasing OBJ: "It just wasn't working for us"
NBC Sports
RB Rankings Downgrades For Week 4 Fantasy Football: Saquon Barkley, Ollie Gordon & More
FantasyLife